Nick Verougstraete

Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters, whereas hydroxychloroquine lacks activity

Suzanne J. F. Kaptein, Sofie Jacobs, Lana Langendries et al. · Proceedings of the National Academy of Sciences · 2020 · 281 citations · Full text

Antiviral Compound, Emerging Infectious Diseases, Lacks Activity +14

Volumetric absorptive microsampling at home as an alternative tool for the monitoring of HbA1c in diabetes patients

Nick Verougstraete, Bruno Lapauw, Sara Van Aken et al. · Clinical Chemistry and Laboratory Medicine (CCLM) · 2016 · 58 citations · Full text

First Report on Brorphine: The Next Opioid on the Deadly New Psychoactive Substance Horizon?

Nick Verougstraete, Marthe M. Vandeputte, Cathelijne Lyphout et al. · Journal of Analytical Toxicology · 2020 · 44 citations · Full text

First identification, chemical analysis and pharmacological characterization of N-piperidinyl etonitazene (etonitazepipne), a recent addition to the 2-benzylbenzimidazole opioid subclass

Marthe M. Vandeputte, Nick Verougstraete, Donna Walther et al. · Archives of Toxicology · 2022 · 39 citations · Full text

Psychoactive Drug, First Identification, Medicine +7

Antiviral treatment of SARS-CoV-2-infected hamsters reveals a weak effect of favipiravir and a complete lack of effect for hydroxychloroquine

Suzanne J. F. Kaptein, Sofie Jacobs, Lana Langendries et al. · 2020 · 31 citations · Full text

Antiviral Treatment, Weak Effect, Emerging Infectious Diseases +15